Potent Neutralizing Activity of Polyclonal Equine Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern
Creators
- 1. Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain;
- 2. Fab'entech, Lyon, France
- 3. Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain
- 4. UMR5151, Health Branch Montpellier, Institut de Recherche pour le Développement, Montpellier, France; Faculté de Pharmacie, CISBR, Université de Montpellier, Montpellier, France
- 5. Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain; Department of Microbiology, Hospital Universitario 12 de Octubre, Madrid, Spain; Department of Medicine, Universidad Complutense School of Medicine, Madrid, Spain; CIBER de Enfermedades Infecciosas (CIBERINFEC—Instituto de Salud Carlos III), Madrid, Spain
Description
Several anti–severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) monoclonal antibodies (mAbs) have received
emergency authorization for coronavirus disease 2019
(COVID-19) treatment. However, most of these mAbs are not
active against the highly mutated Omicron SARS-CoV-2
subvariants. We have tested a polyclonal approach of equine
anti-SARS-CoV-2 F(ab’)2 antibodies that achieved a high level
of neutralizing potency against all SARS-CoV-2 variants of
concern tested including Omicron BA.1, BA.2, BA.2.12 and
BA.4/5. A repertoire of antibodies targeting conserved epitopes
in different regions of the spike protein could plausibly account
for this remarkable breadth of neutralization. These results
warrant the clinical investigation of equine polyclonal F(ab’)2
antibodies as a novel therapeutic strategy against COVID-19.
Files
Potent Neutralizing Activity.pdf
Files
(427.0 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:3c7b191262416b3c8206a15d8ed470a4
|
427.0 kB | Preview Download |